GlassScriptPhysician profile
John Kilian
NPI 1053352260
$9,572.72
in general payments reported to CMS, 2019-2025
25 companies · $411 in 2025
The $411 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,609 · 2020: $699 · 2021: $2,029 · 2022: $1,284 · 2023: $1,097 · 2024: $444 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637 · Consulting Fee: $300 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.27 |
| Consulting Fee | $300.00 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,516.77 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,522.52 | 2019-2021 | |
| Horizon Therapeutics Plc | $911.81 | 2021-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $524.38 | 2019-2021 | |
| Emd Serono, INC. | $439.22 | 2019-2023 | Mavenclad |
| Eisai INC. | $351.97 | 2019-2024 | |
| Abbvie INC. | $351.09 | 2021-2023 | |
| Amgen INC. | $325.98 | 2019-2024 | Uplizna |
| Alexion Pharmaceuticals, INC. | $239.38 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $236.85 | 2019 | |
| Genzyme Corporation | $229.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $197.34 | 2021-2024 | Zeposia |
| Acadia Pharmaceuticals INC | $194.46 | 2019-2021 | |
| Ucb, INC. | $190.52 | 2019-2025 | Rystiggo |
| Acorda Therapeutics, INC | $190.16 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.85 | 2019-2025 | Kisunla |
| Allergan, INC. | $181.36 | 2019-2020 | |
| Celgene Corporation | $124.99 | 2021 | |
| Argenx US, INC. | $124.54 | 2023 | Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $119.04 | 2022 | |
| Avanir Pharmaceuticals, INC. | $117.98 | 2019 | |
| Lundbeck LLC | $102.67 | 2019 | |
| Harmony Biosciences LLC | $97.41 | 2020 | |
| Tg Therapeutics, INC. | $73.43 | 2023 | |
| Amneal Pharmaceuticals LLC | $23.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kilian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.